NewEdge Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.38K Buy
+117
New +$2.87K ﹤0.01% 3887
2025
Q4
– Sell
-45
Closed -$673 – 4205
2025
Q3
$673 Hold
45
– – ﹤0.01% 3918
2025
Q2
$524 Hold
45
– – ﹤0.01% 3797
2025
Q1
$334 Hold
45
– – ﹤0.01% 3758
2024
Q4
$270 Hold
45
– – ﹤0.01% 3724
2024
Q3
$230 Hold
45
– – ﹤0.01% 3673
2024
Q2
$163 Hold
45
– – ﹤0.01% 3663
2024
Q1
$144 Sell
45
-10,000
-100% -$38.7K ﹤0.01% 3689
2023
Q4
$49.2K Sell
10,045
-14
-0.1% -$64 ﹤0.01% 2238
2023
Q3
$54.8K Hold
10,059
– – ﹤0.01% 2072
2023
Q2
$67.5K Sell
10,059
-2,171
-18% -$16.1K ﹤0.01% 1993
2023
Q1
$84K Buy
12,230
+10,032
+456% +$88.4K ﹤0.01% 1807
2022
Q4
$17 Buy
+2,198
New +$17.1K ﹤0.01% 3621

Other funds holding ADPT

NewEdge Advisors's ADPT Position: Q3 2026 in Review

NewEdge Advisors opened a new position in Adaptive Biotechnologies (ADPT) in Q3 2026: 117 shares worth $3.38K. The stake represents ﹤0.01% of the portfolio and ranks #3887 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in ADPT as recently as Q3 2025.

NewEdge Advisors first reported a position in ADPT in Q4 2022 and has held it in 13 quarters since. The position peaked at $84K in Q1 2023. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • NewEdge Advisors held 117 shares of Adaptive Biotechnologies worth $3.38K as of Q3 2026.
  • Adaptive Biotechnologies was a new NewEdge Advisors position in Q3 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of NewEdge Advisors's portfolio in Q3 2026, its #3887 holding.
  • NewEdge Advisors first reported a position in Adaptive Biotechnologies in Q4 2022 and has held it in 13 quarters since.
  • NewEdge Advisors's Adaptive Biotechnologies position peaked at $84K in Q1 2023.
  • 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.